



VGX Pharmaceuticals Announces Issuance of a Key U.S. Patent Covering New Electroporation Technology for Delivery of Macromolecules to Cells

Blue Bell, PA – July 19, 2007 –

VGX Pharmaceuticals today announced that it has been granted U.S. Patent number 7,245,963 titled "Electrode Assembly for Constant-Current Electroporation and Use." The patent covers a new device for the delivery of macromolecules, including DNA plasmids, to tissues.

The VGX technology is based on delivering macromolecules via the application of constant-current electroporation pulses. A key feature of the technology is that changes in tissue resistance during the electroporation procedure are monitored real-time and the pulse-generator adapts in real-time to ensure constant-current pulses are delivered to the tissue of interest. Thus, cell-death due to overheating of cells is minimized by limiting the power dissipation in the tissue in response to changes in the tissue micro-environment.

"We are excited by the issuance of this patent covering a key delivery technology," stated Dr. J. Joseph Kim, President and CEO of VGX. "VGX has implemented the technology in its CELLECTRA™ adaptive constant-current electroporation device for the delivery of DNA plasmid-based vaccines and therapies. The device has been tested extensively in research studies in a large number of different animal models including mice, rabbits, dogs, pigs and non-human primates establishing a broad safety, tolerability and efficacy profile."

The underlying patented electroporation technology was initially developed by ADViSYS, Inc., which is now an important part of VGX since its acquisition in February 2007. VGX has established a dynamic vertically-integrated product development platform encompassing novel DNA vaccine constructs, proprietary electroporation technology for DNA delivery, and an efficient process for the cGMP manufacturing of DNA plasmids. VGX is currently developing a portfolio of DNA based vaccines covering HIV, HPV and influenza as well as DNA therapies for cancer and HIV related cachexia based on growth hormone releasing hormone (GHRH). These potential products are anticipated to be developed for human applications in combination with the CELLECTRA™ electroporation device. VGX plans to initiate the formal IND-enabling toxicology studies for its HPV, influenza, and GHRH product candidates in Q3 2007.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com